Review proposes inflammaging as shared driver of bone and brain aging
This review proposes chronic low-grade inflammation, driven by senescent cells, as a shared upstream driver linking skeletal remodeling and central neuroimmune changes via a bone-brain axis; it labels this an aspirational, hypothesis-generating framework, not an evidence-based standard of care. [1]
Automatic summary · not editorially reviewed
The key findings
The review consolidates evidence into an inflammaging-centered framework proposed as a shared upstream driver of skeletal remodeling and central neuroimmune dynamics via a bone-brain axis. [1]
The review describes elevated cytokines engaging RANKL-dependent osteoclastogenesis in bone and priming microglial neuroinflammation, with osteocalcin declining and sclerostin rising with aging. [1]
Several cited mechanisms rest mainly on murine models or single cohorts and need independent human validation; candidate dual-targeting interventions are not established co-therapies. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Older adults with co-occurring osteoporosis and cognitive impairment, discussed at the level of review evidence
- Summary based on
- Study abstract
- Original publication
- September 4, 2026
Review links osteoporosis and cognitive impairment via inflammaging
The review starts from the rising co-prevalence of osteoporosis and cognitive impairment in aging populations and from a bidirectional epidemiological association supported by multiple meta-analyses. It consolidates existing evidence into an integrative immunopathological framework in which inflammaging — a chronic, low-grade, sterile systemic inflammatory state driven by senescent cells and their senescence-associated secretory phenotype — is examined as a shared upstream driver. The authors state they do not claim to identify novel molecular targets; they synthesize a perspective previously treated in disciplinary silos.
Supporting source [1]
Proposed mechanisms span bone remodeling and microglial neuroinflammation
At the molecular level, the review describes persistently elevated cytokines (IL-6, IL-1β, TNF-α) engaging RANKL-dependent osteoclastogenesis in bone and priming microglial neuroinflammation in the central nervous system. Chronic NF-κB signaling and NLRP3 inflammasome activation, amplified in preclinical models by mitochondrial DNA release via the cGAS-STING axis, are said to sustain this dual output. Within the bone-brain axis, osteocalcin secretion is described as declining with aging while osteocyte-derived sclerostin rises and may antagonize Wnt/β-catenin signaling in both compartments; blood-brain barrier disruption and peripheral immune-cell infiltration are said to further amplify central neuroinflammation.
Supporting source [1]
Evidence levels and proposed dual-targeting interventions remain unvalidated
The review explicitly separates conceptual hypotheses, preclinical cellular and rodent findings, and validated human data. It notes that several widely cited mechanisms — osteocalcin-GPR158-mediated neuroprotection, cGAS-STING-driven neuroinflammation and microbiome-based longevity signatures — rest mainly on murine models or single cohorts and need independent human validation, and that microglial responses in the aging brain reflect a heterogeneous state space rather than a uniform pro-inflammatory conversion. Candidate dual-targeting interventions (senolytics such as dasatinib plus quercetin, NLRP3 inhibitors, cGAS-STING blockade, GLP-1 receptor agonists, microbiota-targeted strategies) are discussed with reference to evidence level, safety concerns and translational limits, not as established co-therapies; dual-endpoint randomized trials enriched for elevated inflammaging biomarkers are said to be needed first.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review proposing a hypothesis-generating framework, not a primary study; it reports no new data, and its mechanisms and candidate interventions remain unvalidated in humans.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Yu M, Wu Y, Wang A, Wang M, Chen Y, Ren H, Zhang Y, Liu Y, Wang S, Fan X. · europepmc.org · September 4, 2026